How should moderate-to-severe mitral regurgitation be managed?

Management of Moderate-to-Severe Mitral Regurgitation

Management depends critically on distinguishing primary from secondary mitral regurgitation, as they have fundamentally different treatment pathways and prognostic implications. 1

Initial Assessment and Classification

First, establish the mechanism of MR using comprehensive echocardiography:

• Primary MR: Structural valve abnormality (leaflet prolapse, flail, perforation)
• Secondary MR: Structurally normal valve with regurgitation due to LV or LA remodeling from cardiomyopathy or atrial fibrillation 2

Quantify severity using integrated methods including EROA, regurgitant volume, vena contracta, and pulmonary vein flow patterns. Note that secondary MR uses lower thresholds (EROA ≥20 mm² vs ≥40 mm² for primary MR) 2.

Management Algorithm for Primary MR

For symptomatic patients with severe primary MR, proceed directly to mitral valve repair at an experienced heart valve center 1. Repair is strongly preferred over replacement.

For asymptomatic severe primary MR, surgery is indicated when:

• LVEF ≤60%
• LV end-systolic dimension ≥40 mm
• New-onset atrial fibrillation
• Pulmonary hypertension (systolic PA pressure >50 mmHg)
• Progressive LA enlargement 1

Mitral valve repair should be performed at experienced centers where surgical outcomes are superior and repair rates exceed 95% 2.

Management Algorithm for Secondary MR

Step 1: Optimize Medical Therapy First

Guideline-directed medical therapy (GDMT) for heart failure is the mandatory first step before considering any valve intervention 2. This includes:

• ACE inhibitors/ARBs or ARNI
• Beta-blockers
• Mineralocorticoid receptor antagonists
• SGLT2 inhibitors
• Diuretics for volume management

Additionally, ensure:

• Cardiac resynchronization therapy (CRT) if QRS ≥130 ms and LBBB pattern
• Revascularization if ischemic etiology with viable myocardium
• Atrial fibrillation management if AF contributes to atrial dilation 2, 3

Reassess MR severity after 3-6 months of optimized therapy, as up to 40-45% may improve 3.

Step 2: Surgical Intervention for Secondary MR

Surgery is Class I indicated for severe secondary MR when:

• Patient is undergoing CABG AND
• LVEF >30% 2

Surgery may be considered (Class IIb) for:

• Severe secondary MR with LVEF >30%
• Persistent symptoms despite optimal GDMT (including CRT)
• Low surgical risk
• No revascularization needed 2

Critical caveat: No survival benefit has been conclusively demonstrated for isolated mitral valve surgery in secondary MR 2. The decision must weigh symptom burden against surgical risk.

Step 3: Transcatheter Edge-to-Edge Repair (TEER)

TEER may be considered for patients at high or prohibitive surgical risk who remain symptomatic despite optimal GDMT 2.

Anatomical eligibility criteria for TEER (per 2020 ACC pathway) 1:

• Confirmed moderate-severe or severe MR on multimodality imaging
• MVA ≥4.0 cm² (exclude mitral stenosis)
• Mean transmitral gradient <5 mmHg
• Grasping zone ≥10 mm without calcification
• For primary MR: flail width <15 mm, flail gap <10 mm
• NYHA Class II-IV symptoms despite GDMT
• Multidisciplinary team consensus recommendation

Avoid futility: Do not perform TEER in patients with:

• LVEF <20-25%
• Severe RV dysfunction
• Severe pulmonary hypertension unresponsive to therapy
• End-stage heart failure without transplant candidacy

Multidisciplinary Team Approach

All moderate-to-severe MR cases should be reviewed by a multidisciplinary heart team including valve cardiologists, heart failure specialists, cardiac surgeons, interventionalists, and imaging experts 1. This is particularly critical for:

• Secondary MR (given lack of clear survival benefit from intervention)
• Patients with borderline surgical risk
• Complex anatomy
• Discordant clinical and imaging findings

Common Pitfalls to Avoid

1. Do not intervene on secondary MR without first optimizing GDMT including CRT when indicated 2
2. Do not use the same severity thresholds for primary and secondary MR 2
3. Do not delay surgery in symptomatic severe primary MR waiting for further LV deterioration 1
4. Do not perform isolated mitral surgery for secondary MR in patients with LVEF <30% 2
5. Do not proceed with TEER without confirming favorable anatomy on TEE with 2D and 3D imaging 1
6. Recognize that secondary MR is dynamic—assess during exercise when clinical picture is unclear 2

Emerging Evidence

Recent data suggest potential benefit of TEER for moderate secondary MR in selected patients, though this requires further validation 4, 5. Current guidelines focus on severe disease, but this may evolve as trial data mature.